Two lots of Teva-Pregabalin 150 mg capsules recalled due to cross-contamination with the drug sertraline

Teva Canada Ltd. is recalling two lots of Teva-Pregabalin 150 mg capsules after routine testing identified that some capsules may be contaminated with the drug sertraline. Patients with a hypersensitivity or allergy to sertraline could experience side effects or have a serious allergic reaction, including an anaphylactic reaction, even at a low exposure.Anaphylactic reaction symptoms can be fatal and may include:Shortness of breath, wheezing, or difficulty breathingSwelling of the eyelids, face, lips, mouth, tongue, or throatUncontrolled shakingFainting or dizzinessTrouble swallowing or speakingWidespread rash, hivesProducts from the recalled lots were first sold in Canada in September 2025 and expire July 31, 2027.Pregabalin is a prescription drug used in adults to treat pain caused by nerve damage due to diabetes, shingles or spinal cord injury. It is also used to treat pain associated with fibromyalgia.Sertraline is a prescription drug used in adults to relieve symptoms of depression, obsessive-compulsive disorder, and panic disorder. Side effects may include nausea, diarrhea, dry mouth, sleep changes, dizziness, tremors or increased sweating.Health Canada is monitoring the company's recall and implementation of corrective and preventive actions.

Status

Active

Key date

Aug 15, 2026

Provinces

National

Added

Aug 16, 2026